Nootropics are compounds proposed to enhance cognitive function with minimal side effects and low toxicity, a definition originally introduced by Romanian chemist Corneliu Giurgea in 1972. The popular usage has expanded substantially to include compounds that fail the original safety criteria, making “nootropic” a marketing category rather than a scientific classification. Evidence-based cognitive enhancement requires separating compounds with established RCT evidence from compounds with hype but limited human data.
Tier 1 nootropics meeting the original safety criteria with established cognitive benefit include creatine monohydrate (5g daily, improves memory under stress/sleep deprivation), L-theanine (200-400mg, reduces anxiety without sedation, pairs with caffeine for attention), omega-3 EPA/DHA (for long-term neural membrane support), and caffeine in moderation (less than 400mg daily, acute attention and alertness). These have 12+ months of human safety data and meaningful RCT evidence.
Tier 2 compounds have evidence but require consideration. Bacopa monnieri (300mg standardized extract) and lion’s mane (750-3000mg dual-extracted) show modest cognitive benefit over 8-12 weeks. Magnesium L-threonate crosses the blood-brain barrier and supports synaptic plasticity. Phosphatidylserine helps age-related cognitive decline. Tier 3 compounds (racetams, noopept, modafinil off-label use, phenibut) have regulatory/safety concerns making them inappropriate for routine use. Commercial “stacks” often combine multiple compounds without individual testing and should be avoided; build protocols from validated monotherapy starting with Tier 1 compounds, adding one compound at a time with 4-week evaluation periods.